Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp., trading under the ticker DMAA, is a blank-check company focused on the domestic pharmaceutical and drug manufacturing sector. The SPAC completed its initial public offering in 2021 and has targeted businesses aligned with reshoring and domestic drug production in the United States. The company filed an 8-K with the SEC on July 20, 2026, accession number 0001213900-26-079678, signaling a material development in its ongoing corporate process. DMAA reflects broader investor interest in domestic healthcare supply chain resilience as a strategic acquisition theme. Sign up for SpacDesk to access the full filing details, timeline, and data on DMAA and hundreds of other SPACs.